Panobinostat is named as an intervention in 2 current clinical trials in our India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel and Norway registers. 1 is recruiting patients now. The most common phase is Phase 4. The sponsor with the most trials is Novartis Pharmaceuticals (1). The most-studied condition is Primary Myelofibrosis.
Of the three regulators tracked here, the first to approve Panobinostat was the EU, on 28 Aug 2015.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
NICE, which decides whether the NHS in England should fund new medicines, has published 1 technology appraisal of Panobinostat. 1 is current, and 1 of it recommends it for at least some patients.
| Appraisal | NICE recommendation | Published | Status |
|---|---|---|---|
| Panobinostat for treating multiple myeloma after at least 2 previous treatments NICE TA380 | Recommended | 27 Jan 2016 | Current |
NICE decisions apply to the NHS in England. In Ireland the HSE decides on reimbursement, advised by the National Centre for Pharmacoeconomics. Titles, categories and dates link to the guidance on nice.org.uk. © NICE 2026 technology appraisal guidance. Available from www.nice.org.uk/guidance. All rights reserved. Subject to Notice of rights. NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication.
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
| Study | Phase | Status | Lead sponsor | Registers |
|---|
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
The same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
3 single-substance products containing Panobinostat on the HPRA medicines list.
No entry for Panobinostat in the EMA, FDA or German BfArM shortage lists we track.
| Lead sponsor | Trials |
|---|---|
| Novartis Pharmaceuticals | 1 |
| Oslo University Hospital | 1 |
A trial with sites in more than one country appears in each of those registers.
2 current trials in our India, China, Germany, France, Spain, Italy, Belgium, Sweden, Poland, Portugal, Turkey, Canada, Mexico, Japan, South Korea, Australia, Israel and Norway registers name Panobinostat (also registered as LBH589) as a drug or biological intervention, as of the registry sync on 4 October 2026. Completed and withdrawn studies are not counted.
Yes. 1 of the 2 trials is recruiting: 1 with sites in Norway. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Novartis Pharmaceuticals (1) and Oslo University Hospital (1). The number in brackets is how many trials each organisation leads.
Yes. The HPRA medicines list includes 3 single-substance products containing Panobinostat, for example Farydak 10 mg hard capsules (pharmaand GmbH). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Not in the lists we track: Panobinostat has no entry in the EMA, FDA or German BfArM shortage registers as of their latest sync.
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Panobinostat works or whether it is effective, and it is not medical advice.
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Panobinostat works or whether it is effective. Each trial links to its own record so you can check it yourself.
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Panobinostat (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 4 Oct 2026. How every register is built: methodology · fixes we have made: corrections log.
